Literature DB >> 10433728

The role of Arg46 and Arg47 of antithrombin in heparin binding.

V Arocas1, S C Bock, S T Olson, I Björk.   

Abstract

Heparin greatly accelerates the reaction between antithrombin and its target proteinases, thrombin and factor Xa, by virtue of a specific pentasaccharide sequence of heparin binding to antithrombin. The binding occurs in two steps, an initial weak interaction inducing a conformational change of antithrombin that increases the affinity for heparin and activates the inhibitor. Arg46 and Arg47 of antithrombin have been implicated in heparin binding by studies of natural and recombinant variants and by the crystal structure of a pentasaccharide-antithrombin complex. We have mutated these two residues to Ala or His to determine their role in the heparin-binding mechanism. The dissociation constants for the binding of both full-length heparin and pentasaccharide to the R46A and R47H variants were increased 3-4-fold and 20-30-fold, respectively, at pH 7.4. Arg46 thus contributes only little to the binding, whereas Arg47 is of appreciable importance. The ionic strength dependence of the dissociation constant for pentasaccharide binding to the R47H variant showed that the decrease in affinity was due to the loss of both one charge interaction and nonionic interactions. Rapid-kinetics studies further revealed that the affinity loss was caused by both a somewhat lower forward rate constant and a greater reverse rate constant of the conformational change step, while the affinity of the initial binding step was unaffected. Arg47 is thus not involved in the initial weak binding of heparin to antithrombin but is important for the heparin-induced conformational change. These results are in agreement with a previously proposed model, in which an initial low-affinity binding of the nonreducing-end trisaccharide of the heparin pentasaccharide induces the antithrombin conformational change. This change positions Arg47 and other residues for optimal interaction with the reducing-end disaccharide, thereby locking the inhibitor in the activated state.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433728     DOI: 10.1021/bi990686b

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

Review 1.  Molecular mechanisms of antithrombin-heparin regulation of blood clotting proteinases. A paradigm for understanding proteinase regulation by serpin family protein proteinase inhibitors.

Authors:  Steven T Olson; Benjamin Richard; Gonzalo Izaguirre; Sophia Schedin-Weiss; Peter G W Gettins
Journal:  Biochimie       Date:  2010-06-02       Impact factor: 4.079

2.  The signature 3-O-sulfo group of the anticoagulant heparin sequence is critical for heparin binding to antithrombin but is not required for allosteric activation.

Authors:  Benjamin Richard; Richard Swanson; Steven T Olson
Journal:  J Biol Chem       Date:  2009-08-06       Impact factor: 5.157

3.  A peptide found by phage display discriminates a specific structure of a trisaccharide in heparin.

Authors:  Tomio Yabe; Ritsuko Hosoda-Yabe; Yoshihiro Kanamaru; Makoto Kiso
Journal:  J Biol Chem       Date:  2011-02-18       Impact factor: 5.157

4.  Conformation of heparin pentasaccharide bound to antithrombin III.

Authors:  M Hricovíni; M Guerrini; A Bisio; G Torri; M Petitou; B Casu
Journal:  Biochem J       Date:  2001-10-15       Impact factor: 3.857

5.  Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism.

Authors:  Trevor P Baglin; Robin W Carrell; Frank C Church; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

Review 6.  Heparin-binding domains in vascular biology.

Authors:  Eva M Muñoz; Robert J Linhardt
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-07-01       Impact factor: 8.311

7.  Mutation of the H-helix in antithrombin decreases heparin stimulation of protease inhibition.

Authors:  Patrick R Gonzales; Timothy D Walston; Laureano O Camacho; Dana M Kielar; Frank C Church; Alireza R Rezaie; Scott T Cooper
Journal:  Biochim Biophys Acta       Date:  2007-08-30

8.  Antiangiogenic platinum through glycan targeting.

Authors:  Erica J Peterson; A Gerard Daniel; Samantha J Katner; Lisa Bohlmann; Chih-Wei Chang; Anna Bezos; Christopher R Parish; Mark von Itzstein; Susan J Berners-Price; Nicholas P Farrell
Journal:  Chem Sci       Date:  2016-08-12       Impact factor: 9.825

9.  Investigation of the Differences in Antithrombin to Heparin Binding among Antithrombin Budapest 3, Basel, and Padua Mutations by Biochemical and In Silico Methods.

Authors:  Réka Gindele; Krisztina Pénzes-Daku; Gábor Balogh; Judit Kállai; Réka Bogáti; Bálint Bécsi; Ferenc Erdődi; Éva Katona; Zsuzsanna Bereczky
Journal:  Biomolecules       Date:  2021-04-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.